Although translation and assay commercialization of the end-to-end process of liquid biopsy is more developed for other cancers—for example, epidermal growth factor receptor (EGFR) mutation testing for lung cancer patients—the experience from such applications is also likely to enhance the HPV field (Table 1). This evidence concerns the gene EGFR and lung carcinoma.